Informations générales (source: ClinicalTrials.gov)

NCT03887806 Statut inconnu
Efficacy Cost Analysis: Retrospective Study on the REMOTEV Study's Ancillary Data
Observational
  • Thromboembolie
University Hospital, Strasbourg, France (Voir sur ClinicalTrials)
mars 2019
mars 2020
29 juin 2024
The implications of the medico-economic impact are essential in the choice of first-line therapists. The economic impact is an important criterion to recommend the privileged use of Direct Oral Anticoagulants (AOD) in first intention.

Etablissements

Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Service Des Maladies Vasculaires - Hta - Nhc - 67091 - Strasbourg - France Dominique STEPHAN, MD, PhD En recrutement Contact (sur clinicalTrials)

Critères

Tous
Inclusion criteria

- Major patient whose age is ≥18 years

- Patient with a diagnosis of MTEV: pulmonary embolism or deep vein thrombosis
diagnosed by the diagnostic reference methods according to the recommendations

- Major patient included in the REMOTEV registry

- Patient having accepted that his data recorded in the REMOTEV register be re-used
for research and publication purposes

Criteria of non-inclusion

- Refusal to participate in the REMOTEV register

- Patient who refused to have his data reused for research and publication purposes

- Pregnant woman

- Subjects under safeguard of justice Subject under guardianship or curatorship